ixazomib + rifampin

This is a **combination of ixazomib and rifampin**. - **Ixazomib** is a small molecule, orally bioavailable proteasome inhibitor, specifically a reversible inhibitor of the 20S proteasome chymotrypsin-like β5 subunit. It is approved for use in combination with lenalidomide and dexamethasone in patients with multiple myeloma who have received at least one prior therapy[1][2][3]. - **Rifampin** is a well-known oral and intravenous antibiotic that acts as a potent inducer of cytochrome P450 enzymes, particularly CYP3A4, and is used mainly to treat mycobacterial infections such as tuberculosis. When **co-administered**, rifampin strongly induces drug-metabolizing enzymes, significantly reducing plasma exposure of ixazomib by 54% (Cmax) and 74% (AUC). As a result, **concomitant use of ixazomib and rifampin leads to a major drug-drug interaction and is contraindicated** because it may reduce the effectiveness of ixazomib in treating multiple myeloma[1][2].

Brand names

NinlaroRifadin

Other names

MLN9708MLN-9708MLN 9708rifampicin